Turkish Entrepreneur Oğuzhan Atay Announced Success in the USA!

Oğuzhan Atay and the Rise of BillionToOne

Turkish entrepreneur Oğuzhan Atay, equipped with a PhD in systems biology from the prestigious Stanford University in the USA, made a revolutionary step in the healthcare sector by founding the company BillionToOne in 2016. The primary goal of his initiative was to develop non-invasive prenatal genetic tests for common diseases such as sickle cell anemia and cystic fibrosis. In line with this aim, BillionToOne, which develops innovative technologies, successfully attracted the attention of investors.

Surprising Increase in Shares

When BillionToOne went public, based in Menlo Park, California, it raised $273 million. Following the IPO, the shares experienced an increase of 80%, rising to $109, which brought the company's market value to $5.8 billion. This growth indicates that investors have shown overwhelming interest and have positive expectations regarding the company's market potential.

Financial Performance and Future Goals

Initially focusing on prenatal genetic testing, BillionToOne gradually expanded its area of activity to cancer testing. As of June 30, 2025, the company achieved $209 million in revenue from 508,000 genetic tests conducted in the last 12 months. This figure represents a 19-fold increase compared to $8 million in revenue in 2021.

Notably, the company recorded a mere $4 million loss in the first half of 2025, which enhances hopes that it could transition to a profitable model in the future.

Technological Innovations and Overall Assessment

Using patented technology, Atay's system can detect even a single letter change from 3 billion DNA bases. This allows for accurate assessment of the genetic disease risk for a potential baby with just one blood sample. While BillionToOne continues its rise with sickle cell and beta thalassemia tests, it also occupies a position described in the medical field as a "valuable vessel" with new tests developed for cancer diagnosis in 2023.

In a statement, Oğuzhan Atay said, “We have exceeded every projection. We are not aiming to change the market, but rather to focus on creating a difference by assuming technological risk based on real data.” This vision and methodology make BillionToOne a strong candidate for further empowerment in the field of health technologies in the future.